Compare OLN & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OLN | SRPT |
|---|---|---|
| Founded | 1892 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.3B |
| IPO Year | N/A | 1997 |
| Metric | OLN | SRPT |
|---|---|---|
| Price | $20.36 | $22.18 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 14 | 29 |
| Target Price | $24.57 | ★ $26.23 |
| AVG Volume (30 Days) | 2.4M | ★ 3.7M |
| Earning Date | 01-29-2026 | 11-03-2025 |
| Dividend Yield | ★ 3.93% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | ★ $6,787,000,000.00 | $2,413,715,000.00 |
| Revenue This Year | $3.82 | $13.83 |
| Revenue Next Year | $2.15 | N/A |
| P/E Ratio | $43.75 | ★ N/A |
| Revenue Growth | 4.68 | ★ 47.15 |
| 52 Week Low | $17.66 | $10.42 |
| 52 Week High | $43.33 | $131.31 |
| Indicator | OLN | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 48.42 | 58.09 |
| Support Level | $20.00 | $21.44 |
| Resistance Level | $21.80 | $23.00 |
| Average True Range (ATR) | 0.90 | 1.31 |
| MACD | 0.15 | 0.48 |
| Stochastic Oscillator | 59.89 | 87.39 |
Olin Corp manufactures and sells a variety of chemicals and chemical-based products. The company organizes itself into three segments based on the product type. The Chlor alkali products and Vinyls segment, which generates the majority of revenue, sells chlorine and caustic soda, which are used in a variety of industries including cosmetics, textiles, crop protection, and fire protection products. The Epoxy segment sells epoxy resins used in paints and coatings. The Winchester segment sells sporting ammunition and ammunition accessories under the Winchester brand. The majority of revenue comes from the United States.
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.